Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma

Alison J. Moskowitz, Sarah McCue Horwitz(New York University), Heiko Schöder(Memorial Sloan Kettering Cancer Center), Paola Ghione(University of Turin), W. Thomas Johnson(Office of Education), Katherine Lopez(Cornell University), María Queralt Salas(Canary Institute of Cancer Research), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Tiffany Chang(Memorial Sloan Kettering Cancer Center), Jennifer Kimberly Lue(Memorial Sloan Kettering Cancer Center), Helen Hancock(Newcastle University), Santosha A. Vardhana(Memorial Sloan Kettering Cancer Center), Marwah Jihad(Memorial Sloan Kettering Cancer Center), Theresa Davey(Memorial Sloan Kettering Cancer Center), Lisa Sarmasti(Memorial Sloan Kettering Cancer Center), Zachary D. Epstein‐Peterson(Memorial Sloan Kettering Cancer Center), Jonathan H. Schatz(University of Miami), Natasha Galasso(Memorial Sloan Kettering Cancer Center), Marcel Smith(Memorial Sloan Kettering Cancer Center), Ellie Casper(Memorial Sloan Kettering Cancer Center), Eric D. Jacobsen(Dana-Farber Cancer Institute), Patricia L. Myskowski(Memorial Sloan Kettering Cancer Center), Robert Stuver(Memorial Sloan Kettering Cancer Center), Anita Kumar(Memorial Sloan Kettering Cancer Center), Sarima Subzwari(Memorial Sloan Kettering Cancer Center), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Katie Ksanznak(Memorial Sloan Kettering Cancer Center), Nivetha Ganesan(Memorial Sloan Kettering Cancer Center), Tayler Miller(Memorial Sloan Kettering Cancer Center), Angela Gibaldi(Memorial Sloan Kettering Cancer Center), Shamir Geller(Tel Aviv Sourasky Medical Center), Win Su Thet(Memorial Sloan Kettering Cancer Center), Kelly Hannigan(Memorial Sloan Kettering Cancer Center)
Blood
November 5, 2024
Cited by 10


Related Papers